Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies - PubMed (original) (raw)
Review
Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies
Shontelle Dodson et al. Annu Rev Med. 2011.
Abstract
Cancer cachexia is a complex metabolic condition characterized by loss of skeletal muscle. Common clinical manifestations include muscle wasting, anemia, reduced caloric intake, and altered immune function, which contribute to increased disability, fatigue, diminished quality of life, and reduced survival. The prevalence of cachexia and the impact of this disorder on the patient and family underscore the need for effective management strategies. Dietary supplementation and appetite stimulation alone are inadequate to reverse the underlying metabolic abnormalities of cancer cachexia and have limited long-term impact on patient quality of life and survival. Therapies that can increase muscle mass and physical performance may be a promising option; however, there are currently no drugs approved for the prevention or treatment of cancer cachexia. Several agents are in clinical development, including anabolic agents, such as selective androgen receptor modulators and drugs targeting inflammatory cytokines that promote skeletal muscle catabolism.
Similar articles
- Advances in cancer cachexia: Intersection between affected organs, mediators, and pharmacological interventions.
Siddiqui JA, Pothuraju R, Jain M, Batra SK, Nasser MW. Siddiqui JA, et al. Biochim Biophys Acta Rev Cancer. 2020 Apr;1873(2):188359. doi: 10.1016/j.bbcan.2020.188359. Epub 2020 Mar 25. Biochim Biophys Acta Rev Cancer. 2020. PMID: 32222610 Free PMC article. Review. - Cancer-Mediated Muscle Cachexia: Etiology and Clinical Management.
Siff T, Parajuli P, Razzaque MS, Atfi A. Siff T, et al. Trends Endocrinol Metab. 2021 Jun;32(6):382-402. doi: 10.1016/j.tem.2021.03.007. Epub 2021 Apr 19. Trends Endocrinol Metab. 2021. PMID: 33888422 Free PMC article. Review. - Deliberation on debilitating condition of cancer cachexia: Skeletal muscle wasting.
Dave S, Patel BM. Dave S, et al. Fundam Clin Pharmacol. 2023 Dec;37(6):1079-1091. doi: 10.1111/fcp.12931. Epub 2023 Jul 20. Fundam Clin Pharmacol. 2023. PMID: 37474262 Review. - Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer.
Dalton JT, Taylor RP, Mohler ML, Steiner MS. Dalton JT, et al. Curr Opin Support Palliat Care. 2013 Dec;7(4):345-51. doi: 10.1097/SPC.0000000000000015. Curr Opin Support Palliat Care. 2013. PMID: 24189892 Review. - On our way to targeted therapy for cachexia in cancer?
Boddaert MS, Gerritsen WR, Pinedo HM. Boddaert MS, et al. Curr Opin Oncol. 2006 Jul;18(4):335-40. doi: 10.1097/01.cco.0000228738.85626.ac. Curr Opin Oncol. 2006. PMID: 16721127 Review.
Cited by
- Body composition and its association with fatigue in the first 2 years after colorectal cancer diagnosis.
van Baar H, Bours MJL, Beijer S, van Zutphen M, van Duijnhoven FJB, Kok DE, Wesselink E, de Wilt JHW, Kampman E, Winkels RM. van Baar H, et al. J Cancer Surviv. 2021 Aug;15(4):597-606. doi: 10.1007/s11764-020-00953-0. Epub 2020 Oct 17. J Cancer Surviv. 2021. PMID: 33067775 Free PMC article. - CT-based screening of sarcopenia and its role in cachexia syndrome in pancreatic cancer.
Khristenko E, Sinitsyn V, Rieden T, Girod P, Kauczor HU, Mayer P, Klauss M, Lyadov V. Khristenko E, et al. PLoS One. 2024 Jan 25;19(1):e0291185. doi: 10.1371/journal.pone.0291185. eCollection 2024. PLoS One. 2024. PMID: 38271373 Free PMC article. - Clinical and prognostic role of sarcopenia in elderly patients with classical Hodgkin lymphoma: a multicentre experience.
Zilioli VR, Albano D, Arcari A, Merli F, Coppola A, Besutti G, Marcheselli L, Gramegna D, Muzi C, Manicone M, Camalori M, Ciammella P, Colloca G, Tucci A. Zilioli VR, et al. J Cachexia Sarcopenia Muscle. 2021 Aug;12(4):1042-1055. doi: 10.1002/jcsm.12736. Epub 2021 Jun 11. J Cachexia Sarcopenia Muscle. 2021. PMID: 34114749 Free PMC article. - Effect of sarcopenia and frailty on outcomes among patients with brain metastases.
Lim MJR, Zhang Z, Zheng Y, Khoo IWL, Ying RCVX, Koh SJQ, Lim E, Ngam PI, Soon B, Low YL, Tan LF, Teo K, Nga VDW, Yeo TT. Lim MJR, et al. J Neurooncol. 2024 Mar;167(1):169-180. doi: 10.1007/s11060-023-04542-w. Epub 2024 Mar 2. J Neurooncol. 2024. PMID: 38430419 - Sarcopenia and Systemic Inflammation Response Index Predict Response to Systemic Therapy for Hepatocellular Carcinoma and Are Associated With Immune Cells.
Zhao M, Duan X, Han X, Wang J, Han G, Mi L, Shi J, Li N, Yin X, Hou J, Yin F. Zhao M, et al. Front Oncol. 2022 Apr 8;12:854096. doi: 10.3389/fonc.2022.854096. eCollection 2022. Front Oncol. 2022. PMID: 35463384 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources